Notice of restricted marketing authorizations for the Lacuna Asia Pacific Health Fund and the Lacuna Global Health Fund
The following information and documents are intended exclusively for interested parties who are domiciled in Germany, Austria or Luxembourg. Only in these countries are the funds shown approved for distribution. The information and documents are not intended for publication in other countries. In particular, citizens of the United States of America are not entitled to access the following contents.
The following information and documents may only be disseminated in the countries in which the funds are distributed.
Healthcare - The Best Asset in Asia-Pacific Region
Focused on the top businesses of the Asia-Pacific healthcare market, the Lacuna Asia Pacific fund combines innovation, a strong economic development and demographics to promising assets. Changing demographics in the Asia-Pacific region and a newly discovered concentration on working health systems provide a fertile breeding ground for longterm yields. We invest in carefully stock picked shares of undervalued businesses and hidden gems in the Asian-Pacific region. We only chose businesses with an understandable strategy and an invested management.
Lacuna Asia Pacific Health
Performance (3 years)*
Global Health - Your Investment into Health
Our globally active, specialized fund Lacuna Global Health unites a low-risk value investing strategy with a long investment horizon and shares from a continually growing healthcare market. Pharma, Biotech and Healthservices are a perfect investment opportunity, as they are generally even yield returns in times of troubled markets. We invest in strong managers, undervalued businesses and analysis fit for buying the whole company at once.
Lacuna Global Healthcare
Performance (1 year)*
Founder and owner Werner Engelhardt sees himself as entrepreneurial investor. During his student years, he founded his first company and has since built the FRONTERIS business group from scratch. All in all, it has around 300 employees today. With this in mind, it's only consistent to use entrepreneurial investing as the philosophical base for the Lacuna fund management.
Werner Engelhardt used his early days as an investor to be the first to bring US REIT funds to Germany. The Lacuna Biotech fund, which followed shortly afterwards, set the groundwork for what would become the FRONTERIS business group. After years of purely entrepreneurial work, Werner Engelhardt returned to his roots and fund management in 2015. Although the funds were initially only meant for the Family Office, the results show convincing work: Find out more about the Lacuna Wachstum TGV
Jane Chen is a senior analyst at Lacuna and is currently based in New York. Her main responsibilities include researching healthcare stocks globally. Before joining Lacuna, she was an Analyst at Amici Capital, a global long/short equity hedge fund with peak AUM of $2.3 billion and had a focus on healthcare and global equities.
Previously, Jane Chen was a merger and acquisitions investment banker and also worked as a value investor at a Munich-based Family Office with strong healthcare orientation and an outstanding track record. She graduated cum laude from Harvard University with a B.A. in History and Economics.
Amita Gupta has been analyzing the Asian market for many years. With professional experience in Hong Kong, India, Singapoore, and South Korea, among others, she provides valuable local expertise in these markets. Her main responsibility are global healthcare stocks, especially those in the Asian region.
She has over 10 years of experience in capital advisory, having previously led buy-side and sell-side due diligence for global private equity funds for their Asian investments in healthcare and TMT sectors. She also has direct healthcare industry experience, having worked for a major pharma company in India. Amita Gupta is an MBA from HKUST/London Business School with a specialization in investing and corporate finance. She is also a distinction-holder Chartered Accountant from India, and has also cleared her level 1 CFA.
Pawan Kaul is a senior analyst at Lacuna. His main responsibility lies in global equities, particularly in the healthcare sector. Prior to Lacuna, he was at Kempen & Co. where he focused on healthcare M&A transactions. Previously, he was at Lighthouse Advisors, an Indian mid-market private equity fund, where he was responsible for sourcing, underwriting and managing deals within healthcare, consumer, media and entertainment sectors with a value investing philosophy. He started his career at KPMG in its Audit and Assurance Services Practice.
Pawan Kaul is a qualified Chartered Accountant and MBA from the London Business School with a specialization in Strategy and Change Management. He is a volunteer business mentor for the Cherie Blair Foundation where he advises women entrepreneurs in emerging markets.
Junior Fund Manager
2014, while finishing his masters degree in finance, Manuel Kohl started supporting the sales division at Lacuna.
After graduation, the banking and business economist now supports Werner Engelhardt at our Family Office. He is responsible for the active management of the group's intern assets.
Manuel Kohl supports the fund management since 2017 with his broad knowledge of capital markets, which was consolidated during his work at a capital management company in Luxembourg.
Since then, his main focus is on the Lacuna Health Care funds. Constantly in contact with our analysts all over the world and in close consultation with Werner Engelhardt, Manuel Kohl is responsible for the daily operations.
Hendrik Kreilinger has been working for Lacuna since early 2017. After a six month internship within our Equity research team he supports our fund management team as Junior Analyst. He focuses on global healthcare shares, especially in developed markets. Before he started with Lacuna, he had already made some experiences in healthcare as an intern for a daughter of Aenovo Group, one of the major European players in contract manufacturing of drugs, dietary supplements, and cosmetics.
Hendrik Kreilinger has a Bachelor of Science in Economics with specialization in finance from the University of Regensburg. He's currently finishing his M.Sc. specializing in quantitative financial economics and corporate finance.
* Past performance is not a reliable indicator of future development. The price performance shown does not take into account any of the investor's expenses such as the sales charge and consulting/sales fees. Exchange rate fluctuations may affect the value of foreign investment.